244 related articles for article (PubMed ID: 10192286)
1. Length variation of helix III in a hammerhead ribozyme and its influence on cleavage activity.
Hammann C; Martinez E; Moosbauer J; Hormes R; Tabler M
Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):25-31. PubMed ID: 10192286
[TBL] [Abstract][Full Text] [Related]
2. Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells.
Homann M; Tabler M; Tzortzakaki S; Sczakiel G
Nucleic Acids Res; 1994 Sep; 22(19):3951-7. PubMed ID: 7524030
[TBL] [Abstract][Full Text] [Related]
3. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
Tabler M; Homann M; Tzortzakaki S; Sczakiel G
Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
[TBL] [Abstract][Full Text] [Related]
4. The influence of imperfectly paired helices I and III on the catalytic activity of hammerhead ribozymes.
Zoumadakis M; Neubert WJ; Tabler M
Nucleic Acids Res; 1994 Dec; 22(24):5271-8. PubMed ID: 7816616
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.
Homann M; Tzortzakaki S; Rittner K; Sczakiel G; Tabler M
Nucleic Acids Res; 1993 Jun; 21(12):2809-14. PubMed ID: 8332489
[TBL] [Abstract][Full Text] [Related]
6. A helix 1-extended hairpin ribozyme exhibits altered cleavage behavior in vitro.
Moosbauer J; Tabler M
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):79-87. PubMed ID: 9149843
[TBL] [Abstract][Full Text] [Related]
7. The antisense sequence of the HIV-1 TAR stem-loop structure covalently linked to the hairpin ribozyme enhances its catalytic activity against two artificial substrates.
Pérez-Ruiz M; Sievers D; García-López PA; Berzal-Herranz A
Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):33-42. PubMed ID: 10192287
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
[TBL] [Abstract][Full Text] [Related]
9. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
Kronenwett R; Haas R; Sczakiel G
J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
[TBL] [Abstract][Full Text] [Related]
10. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
Zhou C; Bahner I; Rossi JJ; Kohn DB
Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
[TBL] [Abstract][Full Text] [Related]
11. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
Phylactou LA; Tsipouras P; Kilpatrick MW
Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
[TBL] [Abstract][Full Text] [Related]
12. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
Sun LQ; Wang L; Gerlach WL; Symonds G
Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
[TBL] [Abstract][Full Text] [Related]
13. Hammerhead ribozymes with a faster cleavage rate.
Clouet-d'Orval B; Uhlenbeck OC
Biochemistry; 1997 Jul; 36(30):9087-92. PubMed ID: 9254134
[TBL] [Abstract][Full Text] [Related]
14. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
[TBL] [Abstract][Full Text] [Related]
15. Structure and function of the hairpin ribozyme.
Fedor MJ
J Mol Biol; 2000 Mar; 297(2):269-91. PubMed ID: 10715200
[TBL] [Abstract][Full Text] [Related]
16. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III.
Denman RB; Smedman M; Kung L
Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076
[TBL] [Abstract][Full Text] [Related]
17. The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells.
Hormes R; Homann M; Oelze I; Marschall P; Tabler M; Eckstein F; Sczakiel G
Nucleic Acids Res; 1997 Feb; 25(4):769-75. PubMed ID: 9016627
[TBL] [Abstract][Full Text] [Related]
18. Unexpected anisotropy in substrate cleavage rates by asymmetric hammerhead ribozymes.
Hendry P; McCall M
Nucleic Acids Res; 1996 Jul; 24(14):2679-84. PubMed ID: 8758995
[TBL] [Abstract][Full Text] [Related]
19. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.
Sioud M
Nucleic Acids Res; 1997 Jan; 25(2):333-8. PubMed ID: 9016562
[TBL] [Abstract][Full Text] [Related]
20. The size of hammerhead ribozymes is related to cleavage kinetics: the role of substrate length.
Hormes R; Sczakiel G
Biochimie; 2002 Sep; 84(9):897-903. PubMed ID: 12458082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
